Cellectar Biosciences
CLRB
8 hedge funds and large institutions have $469K invested in Cellectar Biosciences in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 8 → 8 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
21% less capital invested
Capital invested by funds: $597K → $469K (-$128K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$174K |
| 2 |
US Bancorp
Minneapolis,
Minnesota
|
+$48.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$14.5K |
| 4 |
SIM
Sonora Investment Management
Tucson,
Arizona
|
+$9.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$87K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$24K |
| 3 |
Morgan Stanley
New York
|
-$4.85K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.85K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $246K | – | – | – |
|
2
State Street
Boston,
Massachusetts
| $91K | – | – | – |
|
|
3
US Bancorp
Minneapolis,
Minnesota
| $48K | +$48.5K | +10 | New |
|
4
Northern Trust
Chicago,
Illinois
| $28K | – | – | – |
|
|
TSS
5
Two Sigma Securities
New York
| $18K | +$14.5K | +3 | New |
|
|
AIC
6
AWM Investment Company
New York
| $17K | +$174K | +36 | New |
|
|
7
Morgan Stanley
New York
| $9K | -$4.85K | -1 | -33% |
|
|
SIM
8
Sonora Investment Management
Tucson,
Arizona
| $8.35K | +$9.69K | +2 | New |
|
|
WAM
9
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $2K | – | – | – |
|
10
BlackRock
New York
| $1K | – | – | – |
|
11
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $1K | – | – | – |
|
|
CAM
12
Cormorant Asset Management
Boston,
Massachusetts
| – | -$87K | -18 | Closed |
|
|
ARTA
13
A.R.T. Advisors
New York
| – | -$24K | -5 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$4.85K | -1 | Closed |
|
CLRB Hedge Fund Activity: Q3 2017 in Review
8 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2017, worth a combined $469K — down 21% from $597K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CLRB positions and 3 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was AWM Investment Company, opening a new position worth an estimated $174K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $87K sold.
- 8 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $469K of Cellectar Biosciences stock for Q3 2017, down 21% quarter-over-quarter.
- 4 funds opened new Cellectar Biosciences positions in Q3 2017 and 3 closed out, a net change of +1 holder.
- The largest Cellectar Biosciences buyer in Q3 2017 was AWM Investment Company, an estimated $174K added.
- The largest Cellectar Biosciences seller in Q3 2017 was Cormorant Asset Management, an estimated $87K sold.
Based on aggregated 13F filings for Q3 2017.